{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI+655066",
    "query": {
      "intervention": "BI 655066"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI+655066&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T03:44:15.329Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03706040",
      "title": "A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Risankizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2018-12-27",
      "completion_date": "2021-04-26",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03706040"
    },
    {
      "nct_id": "NCT03105128",
      "title": "A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "placebo for risankizumab",
          "type": "DRUG"
        },
        {
          "name": "risankizumab IV",
          "type": "DRUG"
        },
        {
          "name": "risankizumab SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 931,
      "start_date": "2017-05-10",
      "completion_date": "2021-04-14",
      "has_results": true,
      "last_update_posted_date": "2022-07-06",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 117,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03105128"
    },
    {
      "nct_id": "NCT02054481",
      "title": "BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "BI 655066",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 166,
      "start_date": "2014-02",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-09-19",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Port Orange, Florida • Arlington Hts, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Arlington Hts",
          "state": "Illinois"
        },
        {
          "city": "Bay City",
          "state": "Michigan"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02054481"
    },
    {
      "nct_id": "NCT04862286",
      "title": "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 132,
      "start_date": "2021-07-24",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04862286"
    },
    {
      "nct_id": "NCT03398148",
      "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "risankizumab IV",
          "type": "DRUG"
        },
        {
          "name": "placebo for risankizumab",
          "type": "DRUG"
        },
        {
          "name": "risankizumab SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 1558,
      "start_date": "2018-03-07",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2025-01-16",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 82,
      "location_summary": "Coronado, California • Irvine, California • La Jolla, California + 63 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03398148"
    },
    {
      "nct_id": "NCT03875508",
      "title": "A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        },
        {
          "name": "Autoinjector",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2019-06-04",
      "completion_date": "2020-08-25",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 26,
      "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03875508"
    },
    {
      "nct_id": "NCT03875482",
      "title": "A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo solution for risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2019-05-13",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2021-03-16",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03875482"
    },
    {
      "nct_id": "NCT03478787",
      "title": "Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        },
        {
          "name": "secukinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": null,
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2018-05-08",
      "completion_date": "2020-07-08",
      "has_results": true,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 28,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 24 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478787"
    },
    {
      "nct_id": "NCT03104413",
      "title": "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "placebo for risankizumab IV",
          "type": "DRUG"
        },
        {
          "name": "risankizumab SC",
          "type": "DRUG"
        },
        {
          "name": "risankizumab IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 618,
      "start_date": "2017-12-18",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 114,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03104413"
    },
    {
      "nct_id": "NCT01577550",
      "title": "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "BI 655066 (very high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, i.v.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high medium i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (very low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, s.c.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low medium i.v. dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 39,
      "start_date": "2012-04",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2016-11-16",
      "last_synced_at": "2026-09-13T03:44:15.329Z",
      "location_count": 7,
      "location_summary": "Burbank, California • Miami, Florida • Port Orange, Florida + 4 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577550"
    }
  ]
}